TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00774852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: abatacept placebo
Description: Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine placebo
Description: Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
Study: NCT02063425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 1 pill of 20mg / day, during 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of fluoxetine
Description: 1 pill of 20mg/day, during 3 months
Study: NCT03475316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Dancing
Description: 90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Walking
Description: Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
Study: NCT01504659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine hydrochloride injection
Description: Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flat tonic water (e.g., Canada Dry Tonic Water)
Description: Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
Study: NCT01766154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
Study: NCT03194958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Quitline
Description: Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
Study: NCT00649727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride ER Tablets 10 mg
Description: 2x10mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 10 mg
Description: 2x10mg, single dose fed
Study: NCT02443545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Study: NCT00892281

Intervention type: DRUG
Group type: OTHER
Intervention: doxycycline (Oracea®) 40 mg modified release as monotherapy
Description: Take once daily in the morning

Intervention type: DRUG
Group type: OTHER
Intervention: doxycycline (Oracea®) 40 mg modified release as add-on therapy
Description: Take once daily in the morning
Study: NCT03703024

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raspberry Leaf Extract
Description: Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raspberry Leaf Extract
Description: Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered in a capsule
Study: NCT03243929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Translation of District Sun Safe Policies to Schools
Description: Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
Study: NCT02217696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized reading training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized reading training
Study: NCT00412737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
Study: NCT00708357

Intervention type: DRUG
Group type: OTHER
Intervention: NG-monomethyl-L-arginine
Description: intravenous administration, bolus over 5 minutes, dosage 6mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: NG-monomethyl-L-arginine
Description: intravenous administration, bolus over 5 minutes, dosage 6mg/kg
Study: NCT02268383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
Study: NCT03158064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg by IV~\*300mg
Study: NCT03194958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Quitline
Description: Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Needs Navigator
Description: Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Needs Navigator
Description: Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
Study: NCT04426890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P39
Description: Prefilled syringe (PFS) of 1 mL solution
Study: NCT03948308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample before, during and after infection treatment
Study: NCT01642836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMM
Description: 1. a theory-based community team sports program designed specifically for overweight and obese children,~2. a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~3. a primary care provider behavioral counseling intervention linked to the community and home interventions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Nutrition Education
Description: Enhanced standard care/health and nutrition education intervention:~1. notification of primary care providers about metabolic measures and blood pressure~2. state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights
Study: NCT01441115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study: NCT04426890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P39
Description: Prefilled syringe (PFS) of 1 mL solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P39
Description: Prefilled syringe (PFS) of 1 mL solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Xolair
Description: Prefilled syringe (PFS) of 1 mL solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Xolair
Description: Prefilled syringe (PFS) of 1 mL solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Xolair
Description: Prefilled syringe (PFS) of 1 mL solution
Study: NCT04086966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA-PET/MRI or PET/CT
Description: \[68Ga\]PSMA-PET/MRI or PET/CT
Study: NCT03552016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Riboflavin
Description: The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Riboflavin
Description: The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Riboflavin
Description: The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
Study: NCT02070549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT01402830

Intervention type: OTHER
Intervention: Visual analogue scales (EVAs)
Description: This scale measures the pain intensity.
Study: NCT03934866

Intervention type: RADIATION
Intervention: Low Dose CT scan
Description: Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
Study: NCT04436614

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement:Aloe Vera with Crocus (saffron)
Description: Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
Study: NCT04623541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
Description: R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
Study: NCT04436614

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement:Aloe Vera (simple)
Description: Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary Supplement:Mediterranean Diet
Description: Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
Study: NCT02301208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin combine with IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin combine with IMRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin combine with IMRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin combine with IMRT
Study: NCT01441115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECI301
Study: NCT00388661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin tablet 3 mg once daily
Description: Melatonin tablet 3 mg once daily
Study: NCT04623541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered subcutaneously in cycles of 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered subcutaneously in cycles of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
Study: NCT00388661

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator
Study: NCT04098263

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: LMN-101
Description: variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
Study: NCT01368198

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Balance Lubricating Eye Drops
Description: One instillation of the eye drop in each eye

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIVE™
Description: One instillation of the eye drop in each eye
Study: NCT01782794

Intervention type: OTHER
Intervention: Data collection
Description: Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.

Intervention type: OTHER
Intervention: Data collection
Description: Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
Study: NCT00306774

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: 2,000 IU vitamin D capsule per day for 2 years
Study: NCT00595790

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Study: NCT04324333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital wearable system
Description: Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
Study: NCT00306774

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule per day for 2 years
Study: NCT01845259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Once a day 1,8 mg subcutaneous injection for 16 weeks
Study: NCT03230162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
Study: NCT01951248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP - continuous airway pressure
Description: 3 months of treatment with CPAP treatment
Study: NCT04098263

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LMN-101
Description: variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LMN-101
Description: variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LMN-101
Description: variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
Study: NCT02948439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Brisk walking 3-4 times per week for up to 40 minutes of activity.
Study: NCT05182918

Intervention type: OTHER
Intervention: Substance use disorder treatment
Description: The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
Study: NCT04117633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: Laparoscopic Procedures for Rectopexy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: Laparoscopic Procedures for Rectopexy
Study: NCT03834896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AYMES MADRID
Description: AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
Study: NCT02096107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Tacrolimus, mycophenolate mofetil and steroids
Study: NCT03098095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Moderate physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Moderate physical activity
Study: NCT01845259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide Placebo
Description: Once a day 1,8 mg subcutaneous injection for 16 weeks